A Pierringer settlement is when a plaintiff in a civil lawsuit involving multiple defendants agrees to accept a settlement sum from one or more (but not all) defendants. In exchange, the plaintiff agrees to discontinue their claims against those paying defendants. These defendants would no longer participate in the proceeding (as opposed to a Mary Carter Agreement, in which case the defendants would continue to participate in the proceeding).
The plaintiff assumes all of the financial risks in making such an arrangement. If they underestimate the eventual liability share of the settling defendants, they cannot make up any shortfall from the remaining defendants. Conversely, if the plaintiff eventually recovers a windfall from the settlement (settles for more than is found to be the actual share of liability of the non-settling defendants), they are not entitled to keep the surplus. The court will order that the surplus be used to reduce the amount the non-settling defendants have to pay to satisfy the judgment.
By way of example, assume that there is a claim with damages totalling $1,000,000.00. The suit is against a hospital (with its nurses) and the physicians. The physicians and the hospital are separately represented and have cross-claimed against each other. These two parties at the defence table are outwardly presenting a common front but have left open their right to attack one another during cross-examination. At trial, the trier of fact would establish the respective degrees of fault, if any.
If the hospital and nurses reach a settlement with the plaintiff, say for $400,000.00, the claim against them would be dismissed. The trial against the physicians would now proceed but in the absence of the hospital and its nurses. If the trier of fact determined that the physicians were not liable, that would be the end of the matter. If however it was found that any of the doctors were liable, the trier of fact would then have to determine if the hospital (and nurses) were at fault as well and if so, what were the respective degrees of fault? This would determine how the damages will be apportioned between the parties.
The scenarios above highlight the risks a plaintiff takes when entering into a Pierringer settlement. They do have the comfort of knowing they have received a certain amount of money, but also have to understand and accept that they can never receive more than the total assessed damages. This is so despite taking the risk of receiving less if they are not substantially successful against the non-settling defendants. ONce a settlement is reached, the plaintiffs must then focus their efforts on establishing the liability of the remaining defendants in order to make up the remainder of the damages.
The non-settling defendant(s) are now on their own. Their goal is to implicate the hospital as being the major player in causing the plaintiff’s damages. That will be a somewhat awkward task as the hospital is no longer a party and will be absent from the courtroom unless they or the plaintiffs call the nurses to testify. The plaintiff is unlikely to do so, forcing the non-settling defendants to call them. Calling them in chief to have their evidence before the court means they would normally lose their right of cross-examination.
This very dilemma was faced by the doctors (non-settling defendants) in a recent Ontario Superior Court of Justice decision on the eve of trial. Those defendants sought the right to cross-examine the hospital’s witnesses. They relied on their cross-claim, the dynamics mentioned above and the principles of natural justice.
The court recognized that partial settlements can create both substantial and procedural difficulties. A variety of solutions have been used by the courts in Ontario but the solution that worked here was to allow the non-settling defendants, and the plaintiff, the right to cross-examine any hospital witness no matter which party called them.
At Wise Health Law, our health law lawyers rely on their significant trial and civil litigation experience to provide our clients with exceptional guidance and representation in medical malpractice claims. To find out more about how we can help, contact us online, or at 416-915-4234to schedule a consultation.
In December 2019, Ontario’s Attorney General introduced Bill 161, the Smarter and Stronger Justice Act (the “Act”), which became law on July 8, 2020. The Act hopes to simplify a complex and outdated justice system by bringing changes to how legal aid services are delivered, how class actions are handled, and how court processes are administered.
Of note, the Act has amended the Judicial Review Procedures Act (JRPA) to establish new rules as to when an application for judicial review may be brought.
Any decisions made on or after July 8, 2020 are now subject to a 30-day limit for bringing an application for judicial review unless another Act provides otherwise. Courts, however, retain powers to extend the time for making an application for judicial review if satisfied that there are apparent grounds for relief and that no prejudice or hardship will be incurred by the delay. Before these amendments, the JRPA did not set out any time limits for bringing an application, but courts had powers to extend the time to bring an application if another Act prescribed the limit.
In early August 2020, the Federal Minister of Health granted an exemption under the Controlled Drugs and Substances Act (CDSA) to four terminally ill Canadians to use psilocybin in their end of life care.
Psilocybin is one of the active ingredients/chemicals in “magic mushrooms,” the other is psilocin. Both psilocybin and psilocin are controlled substances under Schedule III of the CDSA. The sale, possession, production, etc. are prohibited unless authorized for clinical trial or research purposes under Part J of the Food and Drug Regulations. Both have been illegal in Canada since 1974. According to Health Canada, there are no approved therapeutic products containing psilocybin in Canada. However, the purified active ingredient, i.e. psilocybin, is being studied in supervised clinical settings for its potential to treat various conditions such as anxiety and depression.